{"id":"NCT04704713","sponsor":"Clinuvel Pharmaceuticals Limited","briefTitle":"Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)","officialTitle":"A Phase III, Randomised, Double Blind, Placebo Controlled, Parallel Group Study, to Evaluate the Safety and Efficacy of Subcutaneous Implants of Afamelanotide (16 mg) in Patients Suffering From Polymorphic Light Eruption (PLE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-05-05","primaryCompletion":"2010-12-09","completion":null,"firstPosted":"2021-01-12","resultsPosted":"2021-03-19","lastUpdate":"2021-03-19"},"enrollment":31,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Polymorphic Light Eruption"],"interventions":[{"type":"DRUG","name":"Afamelanotide","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Afamelanotide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study was to evaluate the safety and efficacy of afamelanotide in patients suffering from polymorphic light eruption (PLE).","primaryOutcome":{"measure":"Severity of PLE Related Pruritus Recorded Using an 11-point Likert Scale","timeFrame":"From Day 0 to Day 120","effectByArm":[{"arm":"Afamelanotide","deltaMin":0.25,"sd":null},{"arm":"Placebo","deltaMin":0.47,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":12},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":15},"commonTop":["Headache","Nasopharyngitis","Diarrhoea","Nausea","Back pain"]}}